ProDots Recombinant Human IL-7 GMP Protein New
ProDots Recombinant Human IL-7 GMP Protein Summary
The ED50 for this effect is 0.1-0.5 ng/mL.
The specific activity of Recombinant Human IL-7 is approximately 4.4 x 105 IU/μg, which is calibrated against human IL-7 WHO Standard (NIBSC code: 90/530).
Asp26-His177, with an N-terminal Met
Produced using non-animal reagents in an animal-free laboratory.
Manufactured and tested under cGMP guidelines.
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from an phosphate buffered saline-based formulation using proprietary excipients.|
|Reconstitution||Reconstitute with cell culture media immediately prior to use.|
|Shipping||The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Store material as supplied, unopened, and unreconstituted at 2-8 °C until use. Stability is a minimum of 8 weeks when stored at 2 - 8 °C as supplied. Refer to lot specific COA for the Use by Date.
The foil pouch is used for shipping and storage only and is not terminally sterilized. GMP ProDots within the weldable bag are prepared under GMP-controlled conditions and protein content is tested to USP <71> guidelines.
GMP-grade Prodots® Recombinant Human IL-7 stimulates proliferation of PHA-activated human peripheral blood lymphocytes. The ED50for this effect is 0.1-0.5 ng/mL.
Comparative tests for function within biologically relevant model systems show equivalence of GMP ProDot™ Proteins and GMP Proteins. Activation of PBMCs after 9 days in culture with ExCellerate™ Human T Cell Media (CCM030), GMP Cloudz Human T Cell Activation Kit (CLD001-GMP) and GMP IL-7 ProDot (PRD247-GMP) or GMP IL-7 protein (247-GMP) shows comparable A. T cell fold expansion and B. phenotypes.
IL-7 (interleukin-7) is a 25 kDa cytokine of the hemopoietin family that plays important roles in lymphocyte differentiation, proliferation, and survival (1‑4). Human
IL‑7 cDNA encodes 177 amino acids (aa) that include a 25 aa signal peptide (3). Human IL-7 shares approximately 60-63% aa sequence identity with mouse, rat, canine and feline IL-7, and 72-76% with equine, bovine, ovine, porcine, feline and canine IL-7. Human and mouse IL-7 exhibit cross-species activity (2, 3). IL-7 is produced by a wide variety of cells in primary and secondary lymphoid tissues, including stromal epithelial cells of the thymus, bone marrow, and intestines (1, 2, 5). Circulating IL-7 is limiting in healthy animals, but increases during lymphopenia (1, 6). IL-7 signals through a complex of the IL-7 Receptor alpha subunit (IL-7 R alpha, also known as CD127) with the common gamma chain ( gamma c) (1). The gamma c is also a subunit of the receptors for IL-2, -4, -9, -15, and -21 (1). IL-7 R alpha is expressed on double negative (CD4-CD8-) and CD4+ or CD8+ single positive naïve and memory T cells, but undergoes IL-7-mediated down‑regulation and shedding during antigen-driven T cell proliferation, and is absent on regulatory T cells (1, 2, 6-11). IL-7 contributes to the maintenance of all naïve and memory T cells, mainly by promoting expression of the anti-apoptotic protein Bcl-2 (9-11). It is required for optimal T cell-dendritic cell interaction (6). IL-7 is expressed early in B cell development prior to the appearance of surface IgM (1, 5, 9). In mouse, IL-7 activation of IL-7 R alpha is critical for both T cell and B cell lineage development, while in humans, it is required for T cell but not for B cell development (4, 9, 12, 13). However, IL-7 functions in both mouse and human pro-B cells to suppress premature Ig light chain recombination during proliferative growth (14, 15).
- Sasson, S.C. et al. (2006) Curr. Drug Targets 7:1571.
- Barata, J.T. et al. (2006) Exp. Hematol. 34:1133.
- Goodwin, R.G. et al. (1990) Proc. Natl. Acad. Sci. USA 86:302.
- Namen, A.E. et al. (1988) Nature 333:571.
- Shalapour, S. et al. (2012) PLoS ONE 7: e31939.
- Saini, M. et al. (2009) Blood 113:5793.
- Park, J.H. et al. (2004) Immunity 21:289.
- Vranjkovic, A. et al. (2007) Int. Immunol. 19:1329.
- Sudo, T. et al. (1993) Proc. Natl. Acad. Sci. 90:9125.
- Seddon, B. et al. (2003) Nat. Immunol. 4:680.
- Schluns, K.S. et al. (2000) Nat. Immunol. 5:426.
- Peschon, J.J. et al. (1994) J. Exp. Med. 180:1955.
- Pribyl, J.A. and T.W. LeBien (1996) Proc. Natl. Acad. Sci. 93:10348.
- Johnson, K. et al. (2012) J. Immunol. 188:6084.
- Nodland, S.E. et al. (2011) Blood 118:2116.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for ProDots Recombinant Human IL-7 GMP Protein
There are currently no reviews for this product. Be the first to review ProDots Recombinant Human IL-7 GMP Protein and earn rewards!
Have you used ProDots Recombinant Human IL-7 GMP Protein?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image